Pentoxifylline (PTX) - An alternative treatment in Graves' ophthalmopathy (inactive phase): Assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial

Página do item simplificado
dc.contributor.authorFinamor Junior, Francisco Estivallet [UNIFESP]
dc.contributor.authorMartins, João Roberto Maciel [UNIFESP]
dc.contributor.authorNakanami, Deise Mitsuko [UNIFESP]
dc.contributor.authorPaiva, Elias Rodrigues de [UNIFESP]
dc.contributor.authorManso, Paulo Gois [UNIFESP]
dc.contributor.authorFurlanetto, Reinaldo Perrone [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2018-06-15T17:22:28Z
dc.date.available2018-06-15T17:22:28Z
dc.date.issued2004-07-01
dc.description.abstractPURPOSE. To investigate the effect of pentoxifylline (PTX) in subjects with inactive Graves' ophthalmopathy (GO) through a specific quality of life (QOL) questionnaire and exophthalmometry readings.METHODS. Eighteen females were randomly divided in two groups. Group A (n=9) was treated with PTX 1200 mg orally/day for 6 months. Group B (n=9) received placebo during the initial 6 months and then PTX for another 6 months. Proptosis measurements were carried out every 3 months and a questionnaire graded from 0 to 10 according to the severity of the symptoms was performed at baseline and after placebo and PTX administration.RESULTS. At baseline, Group A questionnaire score values were 5.5 (median; range 3.5 to 8.0), and 5.0 after 6 months (3.0 to 6.0; p=0.01). In Group B, baseline values were not significantly different after 6 months of placebo: 6.0 (4.5 to 7.0) and 5.5 (4.5 to 7.0), respectively. However, a significant change was observed 6 months after PTX: 4.0 (2.0 to 5.0; p<0.001). Patients in Group A had a progressive improvement of proptosis during PTX: at baseline, 23 mm (median; range 20 to 32); after 3 months, 23 mm (18 to 30; p=0.02); and after 6 months, 23 mm (18 to 30; p=0.005). In Group B, proptosis remained stable during placebo: at baseline, 23 mm (21 to 25); after 3 months, 23 mm (20 to 25); and after 6 months, 23.5 mm (20 to 25). A significant change was observed after 3 and 6 months of PTX: 22 mm (19 to 24; p=0.0006) and 20.8 mm (17 to 25; p=0.0003), respectively.CONCLUSIONS. Pentoxifylline seems to improve the QOL of patients in the inactive phase of GO. The objective findings of the proptosis readings corroborate to suggest that PTX may be an effective and promising drug in the inactive phase of GO. 14: )en
dc.description.affiliationUNIFESP, EPM, Div Endocrinol, BR-04514030 Sao Paulo, Brazil
dc.description.affiliationUNIFESP, EPM, Dept Ophthalmol, BR-04514030 Sao Paulo, Brazil
dc.description.affiliationUNIFESP, EPM, Dept Biostat, BR-04514030 Sao Paulo, Brazil
dc.description.affiliationUnifespUNIFESP, EPM, Div Endocrinol, BR-04514030 Sao Paulo, Brazil
dc.description.affiliationUnifespUNIFESP, EPM, Dept Ophthalmol, BR-04514030 Sao Paulo, Brazil
dc.description.affiliationUnifespUNIFESP, EPM, Dept Biostat, BR-04514030 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent277-283
dc.identifierhttp://www.eur-j-ophthalmol.com/article/pentoxifylline--ptx---an-alternative-treatment-in-graves-ophthalmopathy--inactive-phase---assessment-by-a-disease-specific-quality-of-life-questionnai-art003007
dc.identifier.citationEuropean Journal Of Ophthalmology. Milan: Wichtig Editore, v. 14, n. 4, p. 277-283, 2004.
dc.identifier.issn1120-6721
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/43617
dc.identifier.wosWOS:000222980500001
dc.language.isoeng
dc.publisherWichtig Editore
dc.relation.ispartofEuropean Journal Of Ophthalmology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGraves' ophthalmopathyen
dc.subjectpentoxifyllineen
dc.titlePentoxifylline (PTX) - An alternative treatment in Graves' ophthalmopathy (inactive phase): Assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trialen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos